OCS · Nasdaq, Nasdaq · CIK 0001953530

Oculis Holding AG

Oculis Holding AG’s most recent SEC filing in our snapshot is a Form 6-K filed on Sep 30, 2026. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-CHF 99.0M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
Oculis Holding AG
Tickers
OCS, OCSAW
SEC Central Index Key (CIK)
0001953530
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
ZUG, Switzerland
State or country of incorporation
Switzerland
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#2908 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Oculis Holding AG’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in CHF; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-CHF 18.6MFY2021-CHF 38.7MFY2022-CHF 88.8MFY2023-CHF 85.8MFY2024-CHF 99.0MFY2025
OCS annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-CHF 18.6M-CHF 38.7M-CHF 88.8M-CHF 85.8M-CHF 99.0M
Diluted EPS-CHF 5.84-CHF 11.32-CHF 2.97-CHF 2.12-CHF 1.89
Total assetsCHF 58.0MCHF 37.1MCHF 114.4MCHF 120.4MCHF 236.0M
Cash and equivalentsCHF 46.3MCHF 19.8MCHF 38.3MCHF 27.7MCHF 81.3M

XBRL tags used: netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = CashAndCashEquivalents. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

OCS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 4, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Sep 30, 20266-KReport of a foreign private issuer· period Sep 30, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Oculis Holding AG, by form type:

6-K ×21144 ×4SCHEDULE 13G/A ×3424B5 ×3S-8 ×220-F ×2F-3ASR ×1EFFECT ×1POS AM ×1424B3 ×1F-3 ×1
OCS recent filings
FiledFormWhat it isOriginal
Sep 30, 20266-KReport of a foreign private issuer· period Sep 30, 2026Document · Index
Aug 10, 20266-KReport of a foreign private issuer· period Aug 10, 2026Document · Index
Aug 6, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Aug 6, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Jun 25, 20266-KReport of a foreign private issuer· period Jun 25, 2026Document · Index
Jun 1, 20266-KReport of a foreign private issuer· period May 29, 2026Document · Index
May 14, 20266-KReport of a foreign private issuer· period May 14, 2026Document · Index
May 11, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
Apr 29, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 21, 20266-KReport of a foreign private issuer· period Apr 21, 2026Document · Index
Mar 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 9, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 4, 20266-KReport of a foreign private issuer· period Mar 4, 2026Document · Index
Mar 4, 2026F-3ASRF-3ASRDocument · Index
Mar 4, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Mar 3, 20266-KReport of a foreign private issuer· period Mar 3, 2026Document · Index
Dec 8, 2025EFFECTEFFECTDocument · Index
Dec 5, 2025POS AMPOS AMDocument · Index
Dec 1, 2025424B3424B3Document · Index
Nov 14, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Nov 10, 2025F-3F-3Document · Index
Nov 10, 20256-KReport of a foreign private issuer· period Nov 10, 2025Document · Index
Oct 31, 2025424B5424B5Document · Index
Oct 31, 2025424B5424B5Document · Index
Oct 31, 20256-KReport of a foreign private issuer· period Oct 31, 2025Document · Index
Oct 29, 20256-KReport of a foreign private issuer· period Oct 29, 2025Document · Index
Oct 9, 2025144Notice of proposed sale of securitiesDocument · Index
Oct 6, 20256-KReport of a foreign private issuer· period Oct 6, 2025Document · Index
Sep 23, 2025144Notice of proposed sale of securitiesDocument · Index
Aug 21, 20256-KReport of a foreign private issuer· period Jun 30, 2025Document · Index
Aug 1, 20256-KReport of a foreign private issuer· period Aug 1, 2025Document · Index
Jun 5, 2025S-8Registration of employee benefit plan securitiesDocument · Index
Jun 5, 20256-KReport of a foreign private issuer· period Jun 5, 2025Document · Index
May 9, 20256-KReport of a foreign private issuer· period May 9, 2025Document · Index
May 8, 20256-KReport of a foreign private issuer· period May 8, 2025Document · Index
Apr 15, 20256-KReport of a foreign private issuer· period Apr 15, 2025Document · Index
Mar 14, 2025144Notice of proposed sale of securitiesDocument · Index
Mar 11, 202520-FAnnual report of a foreign private issuer· period Dec 31, 2024Document · Index
Mar 11, 20256-KReport of a foreign private issuer· period Mar 11, 2025Document · Index
Feb 14, 2025424B5424B5Document · Index

Insider filing activity

0 Form 4 filings appear in Oculis Holding AG’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001953530 and XBRL company facts. Oculis Holding AG on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.